2017;3:33 40. S7.7.1-6. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170 6. S7.7.1-7. MERIT-HF Study Effect of metoprolol CR/XL in chronic heart fail- ure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001 7. S7.7.1-8. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675 80. S7.7.1-9. Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classifica- tion. Eur Heart J. 1996;17:1390 403. S7.7.1-10. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients characteristics: a meta-analysis of clinical tri- als. Arch Intern Med. 2000;160:621 7. S7.7.1-11. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldoste- rone blocker, in patients with left ventricular dysfunction after myo- cardial infarction. N Engl J Med. 2003;348:1309 21. S7.7.1-12. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin- receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990 7. S7.7.1-13. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539 4. S7.7.1-14. Tomaselli GF, Zipes DP, What causes sudden death in heart failure? Circ Res. 2004;95:754 63. S7.7.1-15. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;97:155 60. S7.7.1-16. Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic and metabolic remodelling of failing human heart. 